Thursday 19 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterprise solutionsVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Earnings

CorMedix sets $8.32 DefenCath payment rate as it prepares Heron asset purchase

The company reported $355M in cash and $54.5M in quarterly sales, tightened its profit outlook, and flagged a payment reset for DefenCath and a priority FDA review for REZZAYO.

16 Nov 2026 · CorMedix Inc. CRMD · Company news

CorMedix enters 2027 with a $355M cash balance, a pending acquisition and a lower, quarterly-adjusted reimbursement rate for its lead product. Management set out all three on its 12 November call alongside third-quarter results.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): CorMedix Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More EarningsAll →